SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending as its announcement of a $250 million financing amendment, extending its capital runway to 2028, sparks intense debate; bullish traders anticipate a massive short squeeze reminiscent of past parabolic moves, while skeptics raise concerns about potential dilution from the equity line of credit.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is actively discussed as its newly inaugurated Eagle Line pilot production facility highlights its transition towards scalable solid-state battery manufacturing, driving community excitement for future OEM partnerships and impending updates on commercialization and revenue timelines.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after abruptly ceasing its compounded GLP-1 weight-loss pill offering following FDA warnings and legal threats, prompting a polarized community debate over whether this de-risks the company's broader telehealth platform or signifies a critical setback for its growth ambitions, further amplified by Super Bowl advertising efforts.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending amid heightened anticipation for a Supreme Court decision on tariffs that could significantly impact its margins, alongside buzz from new "Nike Mind" products selling out and recent insider buying. The community is polarized, debating whether the stock is a deep value opportunity based on its global brand or a value trap given ongoing margin pressures and discrimination allegations.

Rydex Investments - Invesco CurrencyShares British Pound Sterling Trust

Invesco CurrencyShares British Pound Sterling Trust

The Invesco CurrencyShares British Pound Sterling Trust is trending as recent cooler-than-expected UK CPI data has fueled aggressive market expectations for a Bank of England rate cut, driving bearish sentiment for the pound and highlighting central bank policy divergence.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as the recent departure of its CFO sparks community discussion regarding a potential acquisition, amidst persistent shareholder concerns over management and an upcoming European approval decision for Miplyffa.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is breaking out to new all-time highs, with the community actively discussing how escalating geopolitical tensions in the Middle East and Venezuela are creating a "war premium" on oil and driving significant capital rotation into the energy sector.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

ZETA is trending with significant anticipation surrounding its impending earnings, which many expect to be an 18th consecutive beat-and-raise, as the community actively discusses its robust free cash flow and AI-driven Athena platform as undervalued strengths despite recent market volatility.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is actively discussed after projecting its first-ever quarterly operating profit for Q4 2025 and achieving 100 million battery swaps, with bulls expecting a significant re-rating driven by these milestones and its battery swap "moat," while some in the community remain skeptical of sustained profitability, fearing dilution and citing ongoing market manipulation.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is a trending topic as it strategically pivots to high-performance computing and AI data centers, highlighted by recent acquisitions significantly expanding its power infrastructure. The community is buzzing about its strong positioning as a utility giant for AI, with major partnerships like Google, despite broader market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Petros Pharmaceuticals sank to an all-time low on Wednesday after the company enacted a 1-for-25 reverse stock split, triggering a wave of retail investor chatter and raising fresh concerns about its Nasdaq listing status.The split, which became effective after markets closed Wednesday, aimed to lift Petros’ share price above Nasdaq’s $1 minimum bid requirement.&nbsp;While the maneuver shrank the company’s outstanding share count from roughly 53.5 million to about 2.14 million, it failed to stabilize investor sentiment.&nbsp;Shares tumbled more than 30% intraday Thursday, hitting a split-adjusted low of $0.012 — the stock’s lowest level since its 2020 debut.Despite the steep sell-off, sentiment among retail investors turned “extremely bullish” on Stocktwits amid “extremely high” message volume.One user said, “Given the incentive to exercise at no cost, they may use the remaining shares to drive the price down further,” adding that volume needed to hit at least 30 million before considering a position.&nbsp;<stembedurl>https://stocktwits.com/basijedal/message/613198834</stembedurl>Another said the reverse split “might actually be positive,” citing the post-split price as potentially attractive to speculators. “It probably will still be volatile and could go up,” they added.<stembedurl>https://stocktwits.com/1Black/message/613194524</stembedurl>The steep decline comes as Petros continues to face the risk of delisting from the Nasdaq Capital Market, after previously receiving a noncompliance notice related to minimum stockholders' equity requirements.In parallel, the company is pivoting from its legacy men’s health products toward regulatory-aligned digital health solutions.&nbsp;Petros is developing a software-as-a-medical-device platform that leverages AI and big data to assist pharmaceutical companies with converting prescription drugs to over-the-counter status.&nbsp;Management positioned this strategy as well-timed following President Trump’s April 15 executive order titled&nbsp;“Lowering Drug Prices by Once Again Putting Americans First”—a policy Petros says supports its market transition.“This Executive Order supports the notion that the under-insured and the American population at large will benefit from expanded access to certain drugs,” said Chief Commercial Officer Fady Boctor.&nbsp;He added that Petros’ platform could unlock partnerships with pharmaceutical firms aiming to extend their product lifecycles and reduce drug prices.But questions remain about the company’s financial health.&nbsp;For the year ended Dec. 31, 2024, Petros reported revenue of $5.11 million, down from $5.82 million in 2023.&nbsp;Net losses widened to $14.32 million from $8.16 million, even as loss per share narrowed to $3.34 from $6.35 due to a higher share count.Petros shares have tumbled over 99.9% year-to-date, far underperforming the Dow Jones, down 4.1%, the S&amp;P 500, down 5.1%, and the Nasdaq, down 1.6%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Traders work on the floor of the New York Stock Exchange during morning trading on April 30, 2025 in New York City. (Photo by Michael M. Santiago/Getty Images)

Petros Pharma Stock Plunges To Record Low On 1-For-25 Reverse Split, But Retail Optimism Lingers

Petros Pharmaceuticals hit an all-time low after a 1-for-25 reverse stock split, drawing bullish retail chatter even as delisting risks and mounting losses weighed on the stock.

Equity

Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharma co-vigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, an FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.

Petros Pharmaceuticals Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

Current Price	$0.0077
Prev Close	$0.0074
Open	$0.0072
Dividend Yield	0.00%
50-Day Moving Average	$0.0094
Beta	0.52
Avg. Volume	127,526.75
PE Ratio	0.00

52-Week High	$16.25
52-Week Low	$0.0017
Market Capitalization	$326,266.00
EPS (Annual)	-$83.47
Price to Book	0.10
Revenue Per Employee	$284,002.39
Enterprise Value/EBITDA	N/A

PTPI
Petros Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest PTPI News

PTPIPetros Pharmaceuticals Inc